---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-303104"
form_type: "8-K"
ticker: "KMTS"
cik: "0001877184"
company_name: "KESTRA MEDICAL TECHNOLOGIES, LTD."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:55:09.425486+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kestra Medical preliminary Q2 FY26 revenue up 52% YoY to $22.2-22.6M; gross margin improves to 50.0%

## Summary
- Revenue expected $22.2-$22.6M vs $14.7M prior year (+52% at midpoint).
- Gross profit $11.0-$11.4M (prior $5.8M); gross margin 50.0% vs 39.6%.
- Loss from operations $31.6-$32.0M (prior year $19.1M), reflecting investment in growth.
- Cash and equivalents ~$175M.
- CEO cites commercial momentum and positive unit economics.

## SEC filing metadata
- accession: 0001193125-25-303104
- form_type: 8-K
- ticker: KMTS
- cik: 0001877184
- company_name: KESTRA MEDICAL TECHNOLOGIES, LTD.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877184/000119312525303104/0001193125-25-303104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877184/000119312525303104/d944376d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-303104
- JSON: https://secwatch.observer/filing/0001193125-25-303104.json
- Plain text: https://secwatch.observer/filing/0001193125-25-303104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.